2022 focused update of the 2017 Taiwan lipid guidelines for high risk patients: Coronary artery disease, peripheral artery disease and ischemic stroke

Po Sheng Chen, Meng Lee, Sung Chun Tang, Po Hsun Huang, Hung I. Yeh, Charles Jia-Yin Hou, I. Chang Hsieh, Jiunn Tay Lee, Jiann Shing Jeng, Yi Heng Li

研究成果: Article同行評審

6 引文 斯高帕斯(Scopus)

摘要

The previously published 2017 Taiwan Lipid Guidelines for High Risk Patients becomes the standard guidance of dyslipidemia management for patients with atherosclerotic cardiovascular disease (ASCVD) in Taiwan. New clinical trials of lipid lowering therapy were published successively after 2017. The study results changed the treatment concept of ASCVD. Therefore, an update focusing on the lipid treatment strategy for patients with ASCVD becomes necessary. In this focused update of the 2017 guideline, the treatment targets of low-density lipoprotein cholesterol (LDL-C) for patients with ASCVD were modified. The algorithm of LDL-C lowering therapy was revised. The recommendations in this focused update were made mainly based on the scientific evidence from recently published clinical trials and endorsed by the major medical societies in Taiwan.

原文English
頁(從 - 到)1363-1370
頁數8
期刊Journal of the Formosan Medical Association
121
發行號8
DOIs
出版狀態Published - 2022 8月

All Science Journal Classification (ASJC) codes

  • 一般醫學

指紋

深入研究「2022 focused update of the 2017 Taiwan lipid guidelines for high risk patients: Coronary artery disease, peripheral artery disease and ischemic stroke」主題。共同形成了獨特的指紋。

引用此